This study is currently not recruiting participants.

Multicenter open-label active-controlled randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with acute venous thromboembolism

Study on the Safety and Effects of an Investigational Medication

Not Recruiting
100 years or below
All
Phase N/A

Brief description of study.

The purpose of this study is to assess the safety and efficacy of rivaroxaban and also to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban.

Detailed description of study

The purpose of this study is to assess the safety and efficacy of rivaroxaban and also to evaluate the pharmacokinetics and pharmacodynamics of rivaroxaban.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: acute venous thromboembolism
  • Age: 100 years or below
  • Gender: All

The purpose of this study is to assess the safety and effects of an investigational medication. The study will evaluate how the body processes the medication and how it affects the body, which is known as pharmacokinetics and pharmacodynamics.

Participants in this study will undergo various procedures to monitor their health and how their body responds to the investigational medication. These procedures are designed to ensure the safety of participants and to gather important data about the medication's effects.

  • Who can participate: Eligibility criteria include specific age ranges and key health factors. Detailed criteria will be provided to interested participants.
  • Study details: Participants will take the investigational medication and undergo health monitoring. A placebo, an inactive substance that looks like the investigational medication but does not contain any medicine, may be used for comparison.
Updated on 19 Feb 2024. Study ID: 1409105200

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team